- Studies
have shown a greater than 2.2-fold reduction in narcotic use over the
first 48 hours post-op
- SofPulse
(R) use causes 500% increase in new blood vessels, 59% increase in
surgical wound recovery, 57% reduction in pain at one-hour post-op, 55%
less pain medication and 50% less inflammation
- Bioelectric
medicine is a $17 billion market, projected to exceed $33 billion annually
by 2025
Commercial-stage developer of innovative medical
devices Endonovo Therapeutics Inc.’s (OTCQB: ENDV) proprietary
SofPulse(R) technology is being successfully used by surgeons at New Hanover
Regional Medical Center (NHRMC) in North Carolina to reduce the volume of
opioid prescriptions and remove the need for patients to take narcotics for
pain after surgery.
According to a WECT.com report, NHRMC has been using
SofPulse(R) for six months, during which medical staff noticed a 30-40 percent
drop in post-op narcotic prescriptions (http://ibn.fm/KQSDf). The report quoted urologist Dr. Roc
McCarthy as detailing several benefits of the technology, including faster
recovery times and fewer people asking for pain medication.
The non-invasive SofPulse(R) device uses electromagnetic
waves to reduce inflammation after surgery. It is the flagship product of Endonovo
Therapeutics and its proprietary Electroceutical(R) Therapy, developed for the
treatment of inflammation, cardiovascular disease, and central nervous system
disorders such as traumatic brain injury (TBI), acute concussions,
post-concussion syndrome, and multiple sclerosis.
According to McCarthy, many patients are receptive to the
SofPulse(R) device and opt to use it instead of pain medication because they
are worried about the side effects of opioids, including addiction risks in the
context of the national opioid crisis. The opioid crisis has reached a peak in
the country, putting intense pressure on pharmaceutical companies, health care
providers, and medical facilities to reduce the use of painkillers. This has
created demand for other viable pain control solutions, which were quite
limited until recently.
While the technology behind SofPulse(R) isn’t new, it has
not been fully developed until now, McCarthy added. “It’s just opening the door
to a world of opportunity for people to come up and innovate other ways of
decreasing the amount of pain that people are having,” he said.
SofPulse(R) has prospects to reduce the need and intake of
prescription drugs over the long term. Studies have shown a greater than
2.2-fold reduction in narcotic use over the first 48 hours post-procedure. This
is a positive development in light of 2010 data of the Department of Health and
Human Services, according to which 31% of adverse events and 42% of temporary
harm events among Medicare patients in acute care hospitals were related to
medication.
According to Endonovo data, the technology leads to a 500%
increase in new blood vessels, 59% increase in surgical wound recovery, 57%
reduction in pain at one-hour post-op, 55% less pain medication, and 50% less
inflammation. SofPulse(R) works by restoring key electrochemical processes that
initiate anti-inflammatory and growth-factor cascades necessary for recovery to
occur (http://ibn.fm/JkQNY).
Endonovo’s Electroceutical(R) Therapy is certified for the
treatment of chronic wounds by the Centers for Medicare and Medicaid Services
(CMS) nationwide. The success of this proprietary device is rapidly broadening
the company’s horizons, providing them with new and unique opportunities to enter
the buoyant bioelectric medicine market, which is currently worth $17 billion
and projected to exceed $33.14 billion annually by 2025 (http://ibn.fm/AZEdK).
Endonovo developed its SofPulse(R) technology in
collaboration with researchers and medical centers. The wearable, non-invasive
pain reducer continues to undergo testing as a way of limiting opioid use with
emphasis on post-surgical pain relief and recovery. These technological
developments represent massive, long-term valuation potential for the company.
For more information, visit the company’s website at www.Endonovo.com
NOTE TO INVESTORS: The latest news and updates
relating to ENDV are available in the company’s newsroom at http://ibn.fm/ENDV
About QualityStocks
QualityStocks is
committed to connecting subscribers with companies that have huge potential to
succeed in the short and long-term future. It is part of our mission statement
to help the investment community discover emerging companies that offer
excellent growth potential. We offer several ways for investors to learn more
about investing in these companies as well as find and evaluate them.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the
QualityStocks website applicable to all content provided by QS, wherever
published or re-republished: http://www.qualitystocks.net/disclaimer.php
No comments:
Post a Comment